Ignite Creation Date:
2024-05-06 @ 1:39 PM
Last Modification Date:
2024-10-26 @ 1:17 PM
Study NCT ID:
NCT04082364
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-16
First Post:
2019-09-05
Brief Title:
Combination Margetuximab Retifanlimab Tebotelimab and Chemotherapy Phase 23 Trial in HER2 GastricGEJ Cancer
Sponsor:
Organization:
MacroGenics